Oncolytics Biotech Company Executives
| ONC Stock | CAD 1.32 0.06 4.35% |
Oncolytics Biotech employs about 32 people. The company is managed by 32 executives with a total tenure of roughly 172 years, averaging almost 5.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Oncolytics Biotech's management performance can provide insight into the firm performance.
| Matthew Coffey CEO President, Chief Executive Officer, Chief Operating Officer, Director |
| Wayne Pisano Chairman Independent Chairman of the Board |
Oncolytics |
Oncolytics Biotech Management Team Effectiveness
The company has return on total asset (ROA) of (0.7133) % which means that it has lost $0.7133 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.3822) %, meaning that it generated substantial loss on money invested by shareholders. Oncolytics Biotech's management efficiency ratios could be used to measure how well Oncolytics Biotech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of December 2024, Return On Tangible Assets is likely to drop to -0.75. In addition to that, Return On Capital Employed is likely to drop to -1.03. At this time, Oncolytics Biotech's Other Current Assets are very stable compared to the past year. As of the 2nd of December 2024, Other Assets is likely to grow to 1.05, while Total Assets are likely to drop about 30.5 M.As of the 2nd of December 2024, Common Stock Shares Outstanding is likely to grow to about 71 M, while Net Loss is likely to drop (23.5 M).
Oncolytics Biotech Workforce Comparison
Oncolytics Biotech is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 138. Oncolytics Biotech adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Oncolytics Biotech Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Oncolytics Biotech Price Series Summation is a cross summation of Oncolytics Biotech price series and its benchmark/peer.
Oncolytics Biotech Notable Stakeholders
An Oncolytics Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Oncolytics Biotech often face trade-offs trying to please all of them. Oncolytics Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Oncolytics Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Dr MBA | CEO President | Profile | |
| Matthew Coffey | President, Chief Executive Officer, Chief Operating Officer, Director | Profile | |
| Wayne Pisano | Independent Chairman of the Board | Profile | |
| Alan Tuchman | Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs | Profile | |
| Mary Dillahunty | Vice President - Intellectual Property | Profile | |
| George Gill | Senior Vice President - Regulatory Affairs & Chief Safety Officer | Profile | |
| Kirk Look | Chief Financial Officer | Profile | |
| Ger Amersfoort | Independent Director | Profile | |
| William Rice | Independent Director | Profile | |
| Edwin Levy | Independent Director | Profile | |
| Linda Hohol | Independent Director | Profile | |
| Deborah Brown | Independent Director | Profile | |
| Bernd Seizinger | Independent Director | Profile | |
| Angela Holtham | Independent Director | Profile | |
| Leonard Kruimer | Independent Director | Profile | |
| FCA FCA | Consultant | Profile | |
| Jon Patton | Director Communication | Profile | |
| Wayne MBA | Interim Board | Profile | |
| Andrew Guttadauro | Global Head of Business Development and Presidentident, Oncolytics Biotech (U.S.) Inc. | Profile | |
| Grey Wilkinson | Scientist Medicine | Profile | |
| Andres Gutierrez | Chief Medical Officer | Profile | |
| BBA FCA | Consultant | Profile | |
| Allison Hagerman | Vice President - Product Development | Profile | |
| Amy Levin | Vice Operations | Profile | |
| Rita Laeufle | Chief Medical Officer | Profile | |
| FACP FACP | Consultant | Profile | |
| CA CA | Chief Officer | Profile | |
| J Lievonen | Director | Profile | |
| RN BSN | Vice Operations | Profile | |
| PMP PEng | Vice Development | Profile | |
| BBA CM | Consultant | Profile | |
| Michael Moore | Vice President Investor Relations & Corporate Communications | Profile |
About Oncolytics Biotech Management Performance
The success or failure of an entity such as Oncolytics Biotech often depends on how effective the management is. Oncolytics Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Oncolytics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Oncolytics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.71) | (0.75) | |
| Return On Capital Employed | (0.98) | (1.03) | |
| Return On Assets | (0.71) | (0.75) | |
| Return On Equity | (1.01) | (0.96) |
Oncolytics Biotech Workforce Analysis
Traditionally, organizations such as Oncolytics Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Oncolytics Biotech within its industry.Oncolytics Biotech Manpower Efficiency
Return on Oncolytics Biotech Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 867.2K | |
| Net Loss Per Executive | 867.2K | |
| Working Capital Per Employee | 1.1M | |
| Working Capital Per Executive | 1.1M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.